Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 18, 2022 10:39am
155 Views
Post# 34525199

RE:RE:RE:THTX failure

RE:RE:RE:THTX failureTHTX has really done an awful job of creating a positive narrative around their stock. It would hard to have done worse than they have on this front and I still don't think they can bring themselves to ackowledge that. And that failure has cost us all a tremendous amount when it didn't have to. So, I share in the frustration. But you are right not to sell even though the stock price is lower. Because, despite their inordinately poor stewardship of the stock price/relationship with the capital markets, they likely are getting pretty close to sharing information on TH-1902 that will begin to attract the attention of other investors despite their failings on the IR front. Good data makes up for a lot of IR ills. Had they done a better IR job, however, the stock would never have fallen as far as it has and it would recover to a higher price than it likely will unless they take some really serious steps to acknowledge their faults in this area and make major changes. I hope I am reading the situation incorrectly but I don't see that as being a focus of the CEO yet. While all of us are frustrated, it serves disgruntled shareholders well to consider that the FDA seemed pretty happy w ith TH-1902 so it gave it Fast Track status in the pre-cincial stage - a rarity. Also consider that Soleus, experts in this area of cancer drugs- has become the largest shareholder. Additionally, it seems multiple Chinese drug companies have interest in TH-1902. And most importantly in my eyes, Dr. Rothenberg joined TH as a Scientific Advisor. All of these people/entities are much more qualified than any of us to know the science and they have associated themselves with TH. Stock prices are volatile and move noth higher and lower for all sorts of weird and even unjustified reasons. Those four people/entities have much more credibility than the stock price when judging the worth of TH and the legitimacy of its future prospects. But be as mad as you like at TH management and board as, at least in terms of their management of the narrative around their stock, they have really come up short. Much of what they shared in the one slide on the patients in the recent corporate presentation, they could have shared earlier - why? They were not fully honest/slow in updating shareholders about the delays in the phase 1a trial. That had a bad reputation with investors going into the phase 1a trial and handling communications about it correctly offered them an opportunity to reverse that. Instead, thus far they have made it worse. There is still a chance to get back on the right track - there always is - but we are all paying a heavy price for their shortcomings in this area. 

PWIB123 wrote: I never liquidated my shares even after I became frustrated and threatened to do so when Paul didn't meet his last timeline and we received no true updates.  I've continued to follow along, and they are killing us slowly.  I should have sold everything when I said I intended to.  My loss has only grown greater.  I am hopeful something amazing gets announced soon.  I can see the potential and there are way to many signals aligned, but it really bothers me they haven't come through on much.  It still feels extremely risky compared to what it once did in spite of having more options available to them.  At this point, I might as well hold through the pain and hope for the best.  However, I intend to vote my 50,000 remaining shares against every single person on that board when the time comes.  I don't even care about being logical about it.  They've cost me a lot of money to this point, and they should hear it loud and clear.  My vote won't matter, but it should be made clear investors are upset.  A stock price is a reflection of it's leadership.  They've lost the trust and confidence, and save for a miracle hail mary...which I really don't want to have to rely on...THTX is not looking like a company that is aware of their circumstances.  


<< Previous
Bullboard Posts
Next >>